MedTrace Logo

HEFTME System for Adjuvant Therapeutic Selection of Locally Advanced UTUC Postoperatively：A Perspective Cohort Study

NCT06798246 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2025-01-29

No results posted yet for this study

Summary

This multicenter, real-world study introduces a novel Hematoxylin-eosin staining(H\&E)-based four tumor microenvironment (TME) system (HEFTME system) assisting in prognostic prediction and precise adjuvant treatment selection for laUTUC postoperatively.

Conditions

  • Upper Tract Urothelial Carcinoma

Interventions

DRUG

Chemotherapy

Gemicitabin and cisplatin

DRUG

Immunotherapy

PD-1/PD-L1

DRUG

ADC

ADC drug like RC48

DRUG

Chemotherapy combined with immunotherapy

Chemotherapy combined with immunotherapy

Sponsors & Collaborators

  • Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

    collaborator OTHER

  • Peking University Third Hospital

    collaborator OTHER

  • Fujian Provincial Hospital

    collaborator OTHER

  • Peking University First Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-01
Primary Completion
2027-01-01
Completion
2030-01-01

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06798246 on ClinicalTrials.gov